pharmaceuticals
The pharmaceutical company Bayer achieved sales of €45.6 billion in the financial year 2025, meeting its forecast. Despite difficult market conditions and currency effects, business developed steadily. Bayer expects sales and earnings to remain largely stable in 2026 and is continuing its strategic transformation process.
After 15 years at Merck, Belén Garijo is leaving the company and will take over as CEO of Sanofi at the end of April 2026. Her term as chair of Merck's Executive Board will end as planned, and Kai Beckmann from within the company will take over as her successor. This means that changes are in store at the top of both Merck and Sanofi. Paul Hudson will leave Sanofi in mid-February 2026.
Novartis has broken ground on a new global Biomedical Research Center in San Diego, California. The state-of-the-art research facility is scheduled to open in early 2029, providing jobs for around 1,000 employees and accelerating early drug discovery in key therapeutic areas. The center complements the global Novartis research sites in Cambridge (USA) and Basel (Switzerland) and strengthens the...
Novartis is expanding its digital customer strategy and will be using Agentforce Life Sciences from Salesforce in the future. The aim is to enable personalized interactions with patients and healthcare professionals worldwide. The platform is designed to simplify processes, improve customer insights, and set new standards for efficiency and compliance in healthcare communications. Global rollout...
A new German-Lithuanian collaboration is breaking ground in space health research. Delta Biosciences’ mission to the International Space Station, in partnership with ESA, involves key German research institutes like GSI and DLR. Their joint goal: to explore radioprotective measures that benefit both astronauts and patients on Earth. The project marks a significant step forward in European...
Roche achieved solid sales growth in the first three quarters of 2025. This result was driven by strong demand for novel medicines and diagnostics, as well as a robust pipeline. The company is raising its profit forecast and showing progress with numerous new drugs for the treatment of serious diseases such as Alzheimer's, hemophilia, cancer, and obesity.
Merck is pursuing a focused growth strategy across Life Science, Healthcare, and Electronics. Through targeted acquisitions, investments, and customer-centric business models, the company is expanding its presence in dynamic technology markets. Discover how Merck leverages innovation in rare diseases, semiconductor materials, and digital platforms and what underpins its stable outlook for 2025.
With its new Launch and Technology Center in Darmstadt in Germany, Merck has invested €160 million in the future of drug development. The facility combines research and commercial production to make small molecule therapies available more quickly. Modern technology, sustainable construction, and flexible production environments are designed not only to strengthen the company's competitiveness, but...
In the pharmaceutical industry, extreme accuracy is essential – especially in the production of inhalers, dispensers, and pens. At its Neuenburg site, Nemera relies on Mitutoyo measurement technology to guarantee precise drug delivery. From coordinate measuring machines and optical systems to advanced CT solutions, this partnership drives innovation and sets new quality benchmarks in medical...
Sandoz has announced another step in its sustainability strategy, focusing on solar energy from Spain. Together with Elawan Energy, new plants will be built to cover a significant portion of the electricity needs of European sites from renewable sources. The partnership is part of a long-term plan to significantly reduce the company's environmental footprint.
